Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

2.6%

1 terminated/withdrawn out of 38 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

21%

8 trials in Phase 3/4

Results Transparency

0 of 6 completed trials have results

Key Signals

11 recruiting

Enrollment Performance

Analytics

Phase 1

21(56.8%)

Phase 2

7(18.9%)

Phase 3

5(13.5%)

Phase 4

3(8.1%)

Early Phase 1

1(2.7%)

37Total

Phase 1(21)

Phase 2(7)

Phase 3(5)

Phase 4(3)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (38)

Showing 20 of 38 trials

NCT07487545Phase 1Not Yet Recruiting

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of SSS67 in Healthy Adult Participants Via Single Intravenous Infusion

Role: lead

NCT07445308Phase 1Not Yet Recruiting

The Study is to Evaluate the Safety and Tolerability of SPGL008 Alone or in Combination With BCG in the Patients With NMIBC, and to Determine the RP2D of SPGL008 Alone or in Combination With BCG.To Evaluate the Preliminary Efficacy of SPGL008 Alone or in Combination With BCG.

Role: lead

NCT07058779Phase 1Recruiting

Safety, Tolerability, PK and PD of SSS55 in Healthy Subjects

Role: lead

NCT07038005Phase 1Recruiting

A Phase I Study of SPGL008 in Subjects With Advanced Malignant Tumors

Role: lead

NCT07016490Phase 1Recruiting

A Phase 1 Study of SSGJ-709 in Patients With Advanced Malignant Tumors

Role: lead

NCT07171606Phase 2Recruiting

A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients